| Biological Sciences | Lifetime | 417 | US 245 | 99.95 |
| Environmental Science and Ecology | Lifetime | 160 | US 53 | 99.96 |
| Health, Toxicology and Mutagenesis | Lifetime | 15 | US 5 | 99.93 |
| Cancer Research | Lifetime | 61 | US 35 | 99.71 |
| Genetics | Lifetime | 158 | US 94 | 99.66 |
| Pharmacology | Lifetime | 37 | US 22 | 99.64 |
| Molecular Biology | Lifetime | 745 | US 451 | 99.61 |
| Cellular and Molecular Neuroscience | Lifetime | 472 | US 251 | 98.20 |
| Clinical Pharmacology | Lifetime | 614 | US 252 | 97.35 |
| Spectroscopy and Chemical Instrumentation | Lifetime | 870 | US 359 | 94.27 |
| Pollution | Lifetime | 881 | US 142 | 91.99 |
| Biochemistry | Lifetime | 775 | US 352 | 85.50 |
| Pharmaceutical Science | Lifetime | 773 | US 214 | 80.17 |
| Cellular and Molecular Neuroscience | 2021-2025 | 46 | US 26 | 97.02 |
| Immunology | 2021-2025 | 640 | US 230 | 81.03 |
| Effects and risks of endocrine disrupting chemicals | Lifetime | 4 | US 3 | 99.94 |
| Carcinogens and Genotoxicity Assessment | Lifetime | 5 | US 4 | 99.91 |
| Toxic Organic Pollutants Impact | Lifetime | 8 | US 3 | 99.95 |
| Estrogen and related hormone effects | Lifetime | 16 | US 12 | 99.85 |
| Macrophage Migration Inhibitory Factor | Lifetime | 5 | US 2 | 99.42 |
| Pharmacogenetics and Drug Metabolism | Lifetime | 30 | US 19 | 99.61 |
| Retinoids in leukemia and cellular processes | Lifetime | 29 | US 21 | 99.40 |
| Inflammatory mediators and NSAID effects | Lifetime | 56 | US 32 | 99.37 |
| Nuclear Receptors and Signaling | Lifetime | 22 | US 15 | 99.59 |
| Genomics, phytochemicals, and oxidative stress | Lifetime | 77 | US 35 | 98.96 |
| Cancer-related molecular mechanisms research | Lifetime | 580 | US 156 | 98.30 |
| Environmental Toxicology and Ecotoxicology | Lifetime | 213 | US 50 | 98.68 |
| MicroRNA in disease regulation | Lifetime | 599 | US 172 | 98.10 |
| Analytical Chemistry and Chromatography | Lifetime | 916 | US 290 | 98.07 |
| Circular RNAs in diseases | Lifetime | 433 | US 85 | 97.35 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 346 | US 185 | 97.75 |
| Bioactive Compounds and Antitumor Agents | Lifetime | 277 | US 106 | 96.82 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 421 | US 205 | 97.15 |
| Cancer, Lipids, and Metabolism | Lifetime | 702 | US 340 | 97.54 |
| Drug Transport and Resistance Mechanisms | Lifetime | 758 | US 303 | 97.13 |
| Cancer-related gene regulation | Lifetime | 794 | US 349 | 96.45 |
| Immunotoxicology and immune responses | Lifetime | 57 | US 34 | 96.13 |
| Microbial bioremediation and biosurfactants | Lifetime | 269 | US 72 | 97.24 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 920 | US 403 | 95.73 |
| Phytoestrogen effects and research | Lifetime | 347 | US 149 | 95.32 |
| Synthesis of Indole Derivatives | Lifetime | 137 | US 19 | 94.54 |
| Pesticide Residue Analysis and Safety | Lifetime | 591 | US 77 | 95.04 |
| Kruppel-like factors research | Lifetime | 384 | US 149 | 93.23 |
| Chemical Reactions and Isotopes | Lifetime | 922 | US 435 | 92.56 |
| Synthesis of Tetrazole Derivatives | Lifetime | 288 | US 43 | 87.05 |
| Glutathione Transferases and Polymorphisms | Lifetime | 984 | US 378 | 88.59 |
| GDF15 and Related Biomarkers | Lifetime | 450 | US 151 | 83.18 |
| Curcumin's Biomedical Applications | Lifetime | 998 | US 149 | 82.40 |
| Tannin, Tannase and Anticancer Activities | Lifetime | 355 | US 57 | 80.09 |
| Chemical Safety and Risk Management | Lifetime | 832 | US 372 | 72.66 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 1 | US 1 | 97.06 |
| Nuclear Receptors and Signaling | 2021-2025 | 7 | US 3 | 96.18 |
| Estrogen and related hormone effects | 2021-2025 | 174 | US 72 | 89.87 |
| Synthesis of Tetrazole Derivatives | 2021-2025 | 146 | US 8 | 60.38 |
